Ray Dalio's ADMA Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 472,108 shares of ADMA Biologics, Inc. (ADMA) worth $4.25 M, representing 0.02% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Ray Dalio has maintained this position in ADMA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 285,637 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's ADMA Biologics (ADMA) Holding Value Over Time
Track share changes against reported price movement
Quarterly ADMA Biologics (ADMA) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +285,637 | Add 153.18% | 472,108 | $9.01 |
| Q4 2025 | +126,189 | Add 209.33% | 186,471 | $18.24 |
| Q3 2025 | +60,282 | New Buy | 60,282 | $14.66 |
Ray Dalio's ADMA Biologics Investment FAQs
Ray Dalio first purchased ADMA Biologics, Inc. (ADMA) in Q3 2025, acquiring 60,282 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held ADMA Biologics, Inc. (ADMA) for 3 quarters since Q3 2025.
Ray Dalio's largest addition to ADMA Biologics, Inc. (ADMA) was in Q1 2026, adding 472,108 shares worth $4.25 M.
According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 472,108 shares of ADMA Biologics, Inc. (ADMA), valued at approximately $4.25 M.
As of the Q1 2026 filing, ADMA Biologics, Inc. (ADMA) represents approximately 0.02% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in ADMA Biologics, Inc. (ADMA) was 472,108 shares, as reported at the end of Q1 2026.